Bluewater Toxicology LLC

Bluewater Toxicology LLC was paid $28.14M by Medicaid between Jan 2018 and Jan 2023, across 150 billing codes. Its largest line is G0482, Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed — 22% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in Kentucky

Rank by total paid#5 of 73

Median peer was paid$95K

This provider vs. median296×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	89,119	$3.26M
2019	326,180	$11.64M
2020	227,925	$6.01M
2021	224,843	$3.88M
2022	238,677	$3.29M
2023	2,533	$60K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	22%	69,731	29,213	$6.29M
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	15%	110,419	61,651	$4.30M
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	12%	118,726	56,462	$3.33M
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	12%	26,916	18,455	$3.33M
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	8.1%	30,581	19,469	$2.27M
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	6.5%	51,645	25,506	$1.84M
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	3.3%	82,713	49,371	$923K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	2.7%	66,656	31,587	$755K
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	2.5%	38,798	34,272	$696K
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	2.5%	38,876	34,318	$692K
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	2.4%	37,901	33,574	$686K
87389	Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies	1.3%	29,123	25,898	$355K

138 more codes

80074		<1%	17,248	$240K
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	<1%	18,618	$232K
87522	Neg quan hep c or qual rna	<1%	9,108	$221K
84443	Thyroid stimulating hormone (TSH)	<1%	18,662	$168K
80053	Comprehensive metabolic panel	<1%	27,180	$152K
86780		<1%	22,256	$137K
86480		<1%	7,402	$126K
84481		<1%	15,658	$125K
82607		<1%	18,030	$122K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	27,166	$115K
86803		<1%	12,485	$106K
87426	Infectious agent antigen detection, SARS-CoV-2 (COVID-19)	<1%	4,169	$93K
80050	General health panel	<1%	6,131	$86K
86705		<1%	11,557	$85K
86709		<1%	11,208	$77K
87341		<1%	11,530	$76K
86704		<1%	9,213	$59K
84436		<1%	15,038	$49K
86708		<1%	5,612	$44K
80061	Lipid panel	<1%	6,896	$38K
84439		<1%	6,546	$34K
87521	Neg quan hep c or qual rna	<1%	2,303	$27K
86706		<1%	4,181	$20K
83036	Hemoglobin; glycosylated (A1C)	<1%	5,775	$17K
82746		<1%	2,136	$16K
82248		<1%	8,388	$15K
84480		<1%	1,791	$15K
36415	Collection of venous blood by venipuncture	<1%	19,952	$11K
82728		<1%	1,829	$10K
80361		<1%	3,627	$8K
87340		<1%	2,208	$7K
86376		<1%	1,017	$7K
84403		<1%	421	$5K
80346		<1%	1,855	$5K
81025		<1%	1,185	$5K
83992		<1%	2,963	$5K
80323		<1%	3,290	$4K
87902		<1%	34	$4K
80356		<1%	3,615	$4K
80365		<1%	3,607	$4K
80372		<1%	2,415	$4K
83735		<1%	1,169	$3K
80373		<1%	2,016	$3K
80364		<1%	1,720	$3K
80353		<1%	2,866	$3K
80359		<1%	2,932	$3K
80360		<1%	3,053	$3K
80349		<1%	2,846	$3K
80371		<1%	3,068	$3K
80367		<1%	2,083	$3K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	<1%	34	$3K
80325		<1%	2,820	$3K
80348		<1%	2,365	$3K
80354		<1%	2,221	$3K
80358		<1%	2,195	$3K
86038		<1%	450	$3K
80355		<1%	1,897	$3K
83704		<1%	124	$2K
80362		<1%	1,366	$2K
83540		<1%	760	$2K
80366		<1%	1,268	$2K
86593		<1%	1,274	$2K
80368		<1%	960	$2K
80370		<1%	1,107	$2K
80333		<1%	999	$1K
82670		<1%	204	$1K
84153		<1%	122	$1K
86431		<1%	521	$1K
83001		<1%	130	$1K
82627		<1%	87	$1K
80335		<1%	808	$1K
84702		<1%	209	$1K
80357		<1%	1,060	$1K
81596		<1%	233	$1K
86140		<1%	536	$1K
84270		<1%	88	$1K
80076		<1%	679	$1K
84146		<1%	71	$1K
84154		<1%	85	$955.11
82533		<1%	71	$901.90
80345		<1%	888	$870.32
84445		<1%	39	$854.34
84144		<1%	63	$795.91
86592		<1%	310	$767.14
84466		<1%	67	$696.32
85651		<1%	344	$682.97
83550		<1%	215	$681.02
86147		<1%	15	$678.70
84402		<1%	39	$664.89
80324		<1%	402	$521.54
87086	Culture, bacterial; quantitative colony count, urine	<1%	173	$507.19
83690		<1%	145	$378.78
80363		<1%	274	$363.16
82150		<1%	145	$361.13
83921		<1%	29	$256.93
86696		<1%	19	$224.66
83721		<1%	818	$186.07
85610		<1%	701	$178.92
83090		<1%	16	$170.82
85597		<1%	15	$159.74
85652		<1%	156	$158.08
86695		<1%	19	$153.05
86850		<1%	37	$143.18
84550		<1%	58	$141.77
85306		<1%	15	$136.21
85303		<1%	15	$122.99
82043		<1%	32	$111.31
85300		<1%	15	$105.35
80048	Basic metabolic panel (calcium, ionized)	<1%	16	$94.69
85007		<1%	158	$91.53
80369		<1%	35	$90.19
80321		<1%	58	$86.31
85613		<1%	15	$85.19
86900		<1%	40	$69.95
86901		<1%	39	$67.74
80320		<1%	83	$59.73
81001		<1%	27	$55.64
85730		<1%	242	$50.44
80069		<1%	14	$48.58
84703		<1%	14	$44.78
0031A		<1%	25	$40.00
96372	Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular	<1%	13	$25.35
J0475	Injection, baclofen, 10 mg	<1%	22	$20.00
82947		<1%	13	$18.44
80322		<1%	40	$18.24
0054A		0%	12	$0.00
81220	CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants	0%	16	$0.00
0004A		0%	31	$0.00
81241		0%	12	$0.00
91300		0%	35	$0.00
80338		0%	68	$0.00
0064A		0%	95	$0.00
0001A		0%	15	$0.00
82950		0%	12	$0.00
91306		0%	50	$0.00
91303		0%	24	$0.00
80374		0%	69	$0.00
91301		0%	33	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialBOLUS, JENNIFER (MANAGING PARTNER)